Infectious disease
Weeks after announcing that its lead monoclonal antibody was demonstrating efficacy against the Omicron variant, Adagio Therapeutics CEO Tillman Gerngross steps down.
Synairgen watched its stock plummet 85% after reporting disappointing Phase III results for its inhaled COVID-19 treatment on Feb. 21.
The COVID-19 pandemic and the virus that causes it, SARS-CoV-2, has been resilient, unpredictable and confounding from the very beginning.
The U.S. Centers for Disease Control and Prevention is under fire for failing to publish large swaths of hospitalization data related to the COVID-19 pandemic.
It was noted early in the COVID-19 pandemic that the disease was peculiar — not only was it a respiratory disease, but it created hyper-immune responses.
Clinical Catch-Up for February 21
Two-plus years into the pandemic, it’s obvious that COVID-19 isn’t going away, prompting discussion about what this “new normal” will actually look like.
95% of those surveyed agreed that the pandemic showed the vulnerabilities of the medicine supply chain.
Researchers found that augmenting estrogen levels in postmenopausal women who had tested positive for SARS-CoV-2 might help reduce one’s risk of death from COVID-19.
Research Roundup for February 18
PRESS RELEASES